ClinicalTrials.gg
CompletedNCT04285827Updated Sep 6, 2023

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

A Phase 1 interventional study of CSL889 in Sickle Cell Disease, sponsored by CSL Behring. Completed at 15 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
311th of 559
28 · median 31
Started
2021
with 40 others
Phase 1
98 of 733
13 open now
Registered
494th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 311th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2021, is one of 98 in phase 1, and was the 494th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD). The study involves sequential dose escalation of cohorts with between-group assessments of key safety and PK variables.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SCD as documented in the subject's medical record
  • Aged 18 to 60 years, inclusive
  • Stable SCD for at least 30 days before Day 1. Stable SCD is defined as the subject being at his or her medical baseline, with no evidence of worsening of disease over the last 30 days (including VOC, recent major surgery, hospitalization, serious infection, significant bleeding, cerebrovascular accident, seizures, or IV opioids)(Part A)
  • Uncomplicated VOC requiring parenteral opioid treatment and admission to hospital for management. Uncomplicated VOC is defined as sickle cell pain without the following associated clinical features (Part B):

    • Fever (> 38.5 °C)
    • Hypotension (\< 90/60 mmHg)
    • Hypoxia (\< 90% oxygen saturation on room air, or requiring oxygen therapy to maintain oxygen saturation above 90%)
    • New neurological signs and / or symptoms clinically suggestive of stroke or
    • Signs and / or symptoms of Acute Chest Syndrome, accompanied by any new pulmonary infiltrate on chest radiography (chest X-ray to be performed if clinically indicated and according to local clinical guidelines)
  • Subject is either not taking one of the study permitted SCD therapies (hydroxyurea, L-glutamine, L-glutaminecrizanlizumab, and/or voxelotor) or subject has been taking one or more of those for at least 30 days before Day 1 and is on a stable, well tolerated regimen that is planned to continue without change throughout the study

Exclusion criteria

Exclusion Criteria:

  • History of primary hemorrhagic stroke
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk for bleeding
  • Weight >110 kg (242 lbs)
  • Surgery within 30 days before Day 1 or any preplanned surgeries during the study (minor surgeries may be permitted under local anesthesia before screening, with permission of the medical monitor)
  • Female subjects who are pregnant or breastfeeding
  • Female subject of or fertile male subject either not using or not willing to use an acceptable method of to avoid pregnancy during the study and for 30 days after receipt of CSL889.
  • Treatment with any other drug / biologic that is newly approved for SCD during the conduct of this study within 90 days before Day 1. Exceptions: crizanlizumab [Adakveo®] and voxelotor [Oxbryta®] ] are permitted (where prescribed).
  • Treatment with another product within 30 days or within 5 half-lives of the product (whichever is greater) before Day 1
  • Vaccination within 30 days before Day 1, or planned vaccination during the study
  • Body-mass index \< 16 kg/m2 or weight \< 50 kg (110 lbs)
  • History of anaphylactic-type reactions, transfusion related reaction, asthma, or disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    CSL889 Cohort A1 (Dose 1)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort A2 (Dose 2)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort A3 (Dose 3)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort A4 (Dose 4)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort A5 (Dose 5)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort A6 (Dose 6)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort B1 (low dose)

    CSL889 administered as a single IV infusion

    Biological: CSL889

  • Experimental
    CSL889 Cohort B2 (high dose)

    CSL889 administered as a single IV infusion

    Biological: CSL889

Interventions

  • BiologicalCSL889

    Administered as an IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with treatment-emergent adverse events (TEAEs) by Cohort

    Time frame: Up to 32 days after start of CSL889 infusion

  2. Percentage of subjects with TEAEs by severity by Cohort

    Time frame: Up to 32 days after start of CSL889 infusion

  3. Percentage of subjects with TEAEs by causality by Cohort

    Time frame: Up to 32 days after start of CSL889 infusion

Secondary outcomes

  1. Maximum observed serum concentration (Cmax) of CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  2. Area under CSL889 serum concentration-time curve (AUC) from time 0 to time t (AUC0-t) by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  3. Maximum observed serum concentration (Cmax) of CSL889 by Cohort AUC extrapolated to infinity (AUC0-inf) by CSL889 dose level

    Time frame: Up to 32 days after CSL889 infusion

  4. Time of Cmax (tmax) of CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  5. Terminal half-life (t1/2) of CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  6. Clearance (CL) of CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  7. Volume of distribution (Vz) of CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

  8. Percentage of subjects with detectable antibodies to CSL889 by Cohort

    Time frame: Up to 32 days after CSL889 infusion

07

Study locations

15 sites
  • University of Illinois Hospital and Health Science Systems
    Chicago, Illinois 60612, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27834, United States
  • Ohio State University
    Columbus, Ohio 43201, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Amsterdam UMC Academic Medical Center
    Amsterdam, Netherlands
  • Erasmus University Medical Center
    Rotterdam, Netherlands
  • Liverpool University Hospital
    Liverpool, United Kingdom
  • Guys and St. Thomas
    London, United Kingdom
  • University College London Hospital
    London, United Kingdom
  • Manchester University Hospitals NHS Foundation Trust / Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • Early Phase Unit
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2023, 26 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 26 months is close to that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2020
First posted
Feb 26, 2020
StartActual
May 20, 2021
Primary completionActual
Jul 24, 2023
CompletionActual
Jul 24, 2023
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04285827
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Feb 26, 2020
Start date
May 20, 2021
Primary completion
Jul 24, 2023
Completion
Jul 24, 2023
Last update
Sep 6, 2023

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion